Release date: 2024-08-23 17:43:44 Article From: Lucius Laos Recommended: 115
Alpelisib effectively inhibits the proliferation of HR/HER2- breast cancer cells by inhibiting the PI3K pathway, which is especially suitable for advanced cases with PIK3CA mutations.
According to the latest market survey data, the price of 150mg*28 tablets of Laos Lucius version of Alpelisib is about 1755 yuan. The India export version offers a combination of 200mg*14 capsules and 150mg*28 capsules, priced at about 3900 yuan.
In contrast, the price of the Hong Kong export version of 150mg*56 capsules is higher, about 43,800 yuan. This price difference may be related to factors such as production location, specifications, and market demand.
The above price information can help patients make a more informed choice when purchasing. After understanding the market price of the different versions, we can further focus on the drugs produced by Lucius and understand the quality of the drugs.
Lucius Pharmaceutical has introduced advanced pharmaceutical equipment, focusing on the production of anti-tumor, antiviral, biologics, cephalosporins and commonly used drugs. All equipment complies with EU pharmaceutical standards to ensure efficient and safe medicines.
The company strictly follows the international quality management system standards and always puts the health and safety of patients first. We have established a comprehensive quality management system, and strictly monitor and test every link of raw material procurement, production, storage and sales. Through continuous improvement and technological innovation, Lucius Pharma is committed to ensuring that every drug meets the highest quality standards and becomes your trusted guardian of health.
Knowing Lucius Pharmaceutical's quality and manufacturing standards, patients can use their medications with greater peace of mind. Next, this article will introduce the precautions when taking medication.
Understanding these considerations can help avoid common problems and allow your medication to get the most out of it.
Fasting blood glucose (FPG) and HbA1c are tested to optimize glycemic control before starting treatment. Fasting blood glucose should be monitored weekly and HbA1c should be checked regularly initially, especially in patients with risk factors for hyperglycemia.
If new or worsening respiratory symptoms develop, discontinue apellix immediately and assess for progression to pneumonia. Apellix should be permanently discontinued after pneumonia is confirmed, and patients are advised to report any new or worsening respiratory symptoms.
Understanding the above medication considerations can help effectively manage the potential risks during Apellix treatment.
[Warm tips] Please maintain communication with your doctor during the use of Apellis, check regularly, and report any discomfort during the medication. Timely feedback can help adjust the treatment plan in time to make the treatment go smoothly.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: